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activity (P < .01) and increased VWF antigen level after
pretreatment (P< .01) as comparedwith the non-thrombotic
patients; three out of 8 (37.5%) showed more than 60%
decrease in plasma ADAMTS13 activity. The level of
ADAMTS13 activity dropped in the 49 patients with aGVHD
as compared with healthy controls (P< .01), but therewas no
signiﬁcant difference between patients with and without
aGVHD. Twenty-ﬁve patients showed decreased plasma
ADAMTS13 activities only at the onset of aGVHD occurrence
(P < .01), in which two of them decreased more than 60%
(6%). Logistic regression analysis showed that the ADAMTS13
activity declined by more than 60% was the risk of throm-
bosis (P < .01).
Conclusions: We observed decreased plasma ADAMTS13
activity and increased plasma level of VWF antigen in
patients following HSCT after pretreatment, especially in the
patients with thrombotic complications. A decrease more
than 60% in plasma ADAMTS13 activity is the risk factor of
thrombotic complications. Therefore, the plasma ADAMTS13
activity could be an important parameter for the develop-
ment of vascular disorder, which has a potential role for the
early diagnosis of thrombotic complications.365
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Background: Hemostatic disorders are common and
potentially fatal complications in patients undergoing
hematopoietic stem-cell transplantation (HSCT). Limited
data exist on early diagnosis and prevention of these
complications. In this study, we retrospectively investigated
the outcome and risk factors associated with thrombotic and
bleeding complications in HSCT recipients.
Methods: From April 2004 to December 2011, 680 hemato-
logic patients receiving HSCT were enrolled in the study, and
their clinical manifestation and laboratory parameters were
analyzed for evaluating the outcome of hemostatic compli-
cations and related risk factors.
Results: Overal incidence of thrombotic complication, which
included 12 veno-occlusive diseases (VOD), 2 transplantation
related thrombotic microangiopathy (TA-TMA), 1 pulmonary
embolism (PE) and 1 deep vein thrombosis (DVT), was 2.4%
(16 cases). The overall mortality after thrombotic events was
68.8% (11 cases) in all HSCT recipients with thrombotic
complications. A total of 510 HSCT recipients (72.5%) devel-
oped bleeding events, including minor bleeding of 67.1%,
moderate bleeding of 28.4%, and severe bleeding of 3.9% of all
bleeding patients. By bleeding sites, 218 patients developed
hemorrhagic cystitis. Other organs of hemorrhage involved
skin or mucosa (46.5%), gastrointestinal tract (21.1%), vagina
(9.3%), and respiratory tract (1.3%). By risk factors analysis,
CD33 mAb use and preparative regimen containing total
body irradiation were signiﬁcantly associated with the
occurrence of thrombotic disorders (P < .05). Thrombocyto-
penia, grade 2-4 acute graft-versus-host disease (aGVHD),
allogeneic transplantation and infection were independent
risk factors for bleeding complication (P< .05). Polyomavirus
and grade 2-4 aGVHD were risk factors for hemorrhagic
cystitis (P < .05). The number of hemorrhagic sites was
signiﬁcantly correlated with bleeding severity (P < .05).Neither thrombotic nor bleeding disorders was correlated
with age, disease category, gender, transplantation types,
routine hemostatic parameters, or biochemical indicators.
Survival rate was correlated with the bleeding site and
intensity of bleeding disorders (P < .01). Respiratory and
gastrointestinal bleeding independently increased the
mortality of HSCT recipients, while overal cumulative
survival was decreased in patients with thrombotic compli-
cations. In addition, PAI-1 level in the HSCT recipients with
thrombotic complications were signiﬁcantly higher than
other complications (P < .01).
Conclusions: Our study suggested that HSCT patients with
thrombotic complications experienced high mortality while
the HSCT recipients with bleeding disorders had high
morbidity. Hence, early diagnosis and therapy of hemostatic
complications are crucial to improve the prognosis of HSCT
recipients.366
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Background:Many individual and treatment-related factors
impact post-allogeneic hematopoietic cell transplant (HCT)
immune reconstitution (IR). Our institution measures
lymphocyte subsets/activation status with 8-color ﬂow
cytometry panels at important milestones (e.g., development
of GVHD, day +365 evaluation), allowing for sensitive
monitoring of GVHD and post-HCT IR. We sought to identify
whether previously unrecognized patterns of CBC data and
lymphocyte subsets are associated with GVHD status.
Methods: 288 allogeneic HCT recipients have undergone
clinical IR testing at our institution since 2010. Included in
this analysis are 43 HCT patients who underwent testing for
IR with our updated antibody panel (CD3, CD4, CD8,
CD8beta, CD19, CD25, CD27, CD45, CD45RO, CD56, CD69, IgD,
and HLA-DR). Patients were classiﬁed according to clinical
status: no GVHD (9), active acute (3), resolved acute (6),
active chronic (18), and treated chronic GVHD (7). Differ-
ences in cell populations were determined by Kruskall-
Wallis tests. Multivariate pattern recognition techniques of
principal components/factor analysis (PCA/FA) and discrim-
inant analysis (DA) were used for exploratory predictive
modeling.
Results: Patients with active chronic GVHD had a signiﬁcant
increase in CD4-CD8- T cells (P ¼ .01) and trended towards
increased in NKT cells (P ¼ .06). PCA/FA revealed 3 factors
that account for 88% of the variability of the IR data (Factor
1¼CD4+, CD8+, and naïve T cells, Factor 2¼naïve and
switchedmemory B cells, and Factor 3¼absolute lymphocyte
counts [ALC] and platelet counts). By applying all variables
from the 3 factors in a DA model (Table), the ability to
discriminate between active vs. no GVHD approached
statistical signiﬁcance (P ¼ .06). Adding CD4-CD8- T cells and
NKT cells to the model did not allow for discrimination of
active vs. treated chronic GVHD. Lymphocyte activation (e.g.,
by HLA-DR or CD69 expression) could be identiﬁed in a few
patients who did not have overt GVHD or infections.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S293Conclusions: 3 independent factors e subsets of T cells, B
cells, and total lymphocyte counts along with platelet
counts e account for the majority of variability in IR in this
cohort. CD4-CD8- T cells and NKT cells may be emerging
biomarkers of chronic GVHD activity. Lymphocyte activation
without overt GVHD adds to the complexity of the study of
post-HCT IR. Withmore patient data, predictive classiﬁcation
of GVHD status by peripheral blood cell subset testing may
become possible.Table
Factor and Discriminant Analysis
Factor Percent
of Data
Variance
Cumulative
Percent
of Variance
Cumulative
Percent
Misclassiﬁed
on DA
Cumulative
P
Factor 1 (CD4+,
CD8+, CD45RO- T
cells subsets)
33.91 33.91 41.9 0.54
Factor 2 (naïve B
and switched
memory B cell
subsets)
28.19 62.10 35.0 0.10
Factor 3 (ALC +
platelet count)
25.54 87.65 13.3 0.06367
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Background: Allogeneic hematopoietic cell transplantation
(HCT) can be curative in patients with acute myeloid
leukemia (AML), but relapse after HCT continues to be
a leading cause of mortality. Treatment options for these
patients are limited. Hypomethylating (HM) agents such as
5-azacytidine and 5-aza-2'-deoxycytidine (gemcitabine)
have immunomodulatory properties including augmenting
tumor antigen presentation that may enhance graft-versus-
leukemia (GVL) effect. Moreover, inhibitory effects of these
agents on T-cell activation and cytokine production may lead
to low incidence of graft-versus-host-disease (GVHD). Our
aim was to describe the outcomes, including response,
survival, and incidence of GVHD, in patients treated with HM
agents for relapsed AML or loss of donor chimerism (LDC)
after HCT.
Methods: Subjects were patients with relapsed AML or LDC
after allogeneic HCT for AML or high-risk myelodysplastic
syndrome (MDS) whowere treatedwith either 5-azacytidine
or decitabine at the University of Pittsburgh Cancer Institute.
Relapse was deﬁned as a period of complete remission (CR)
after HCT followed by re-occurrence of>5%myeloid blasts or
cytogenetic abnormalities on bone marrow biopsy. LDC was
deﬁned as <100% donor chimerism without relapse. Retro-
spective analysis was performed to determine response to
HM agents, overall survival from time of relapse or LDC, and
incidence of GVHD.
Results: Thirteen patients were identiﬁed, whose median
age was 57 years (22-62), and median time to relapse after
HCT was 124 days (30 to 847). Seven patients receivedmyeloablative conditioning regimens, and 6 patients
received reduced-intensity conditioning. Nine patients had
relapsed AML, and 4 patients had LDC. Ten patients were
treated with decitabine and 3 patients were treated with 5-
azacytidine, with median cycles received of 4 (1-9). After
hypomethylating agents, 9 of 12 (75%) evaluable patients had
a CR, and 3 patients had progressive disease. Eight of 10 (80%)
evaluable bone marrow biopsies revealed 100% donor
chimerism after treatment with a HM agent. Grade I-IV acute
GVHD of the liver occurred in 6 patients, 3 of whom had
isolated liver involvement. Median survival was 308 days
(44-857) from time of relapse or LDC, and 7 patients are alive
at time of analysis and remain in CR.
Conclusions: HM agents in patients with relapsed AML can
be effective in reversing loss of donor chimerism and
inducing CR. This may be due to epigenetic changes and
subsequent immunomodulatory effects that enhance GVL
effect. There may be a relationship between use of these
agents with development of acute liver GVHD, and further
exploration into pathophysiology and predisposing factors
are warranted. The use of HM agents as a maintenance
strategy in patients at high risk of relapse after HCT should be
further explored.368
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Background: The Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) is predictive of non-relapse
mortality (NRM) and overall survival (OS) after allogeneic
stem cell transplant (SCT). However, the HCT-CI has been less
well validated in the older SCT patient population. We
hypothesized that the HCT-CI could have less discriminative
ability in this population, where multiple comorbidities are
common.
Methods: We performed a retrospective study of patients
50 years of age who underwent SCT at UCSF, where HCT-CI
was recorded prospectively as part of routine clinical care
starting in 2007. Outcomes measured included NRM and OS,
as well as grade 3-4 non-hematologic adverse events to 100
days post-SCT, duration of hospital stay, and risk of re-
hospitalization with the ﬁrst 100 days. Kaplan Meier
methods with log-rank tests were used for analysis of NRM
and OS; Student's t test or chi-square test were used for the
remaining outcome measures.
Results: We identiﬁed 59 patients 50 years of age with
complete HCT-CI data. The median age was 60 years (range
50-74) and 31 (53%) of the patients were male. Most SCTs
were for AML (n¼30, 51%) orMDS (n¼9,15%). SCTswere non-
myeloablative in 24 patients (41%) and conditioning was
ﬂudarabine/busulfan-based in 53 patients (90%). Median
follow up was 22 months.
Twelve patients had HCT-CI score of 0 (20%), 19 had HCT-
CI score of 1-2 (32%) and 28 had HCT-CI score 3 (47%). High
HCT-CI score (3) was associated with signiﬁcantly
decreased OS (median OS not reached for HCT-CI 0-2 vs 14
months for HCT-CI 3; hazard ratio 2.2, P ¼ .02). This
remained signiﬁcant in multivariate analysis that included
age, KPS, treatment intensity, and the presence or absence of
